Patent 10,995,346 Analysis: Claims and Landscape Assessment
What are the core claims of Patent 10,995,346?
Patent 10,995,346, granted by the United States Patent and Trademark Office (USPTO) on March 2, 2021, relates to a method of treating disease by administering a specific pharmaceutical compound. The patent claims include:
- A method involving administering a compound with a specified chemical structure.
- The method’s application to certain diseases, including neurodegenerative conditions.
- Optional combination with other therapeutic agents.
- Specific formulations and dosage regimens.
The patent’s claims are divided into independent and dependent claims. The independent claims define the primary method of treatment, while dependent claims specify particular compounds, doses, formulations, or treatment combinations.
Key points:
| Claim Type |
Scope |
Limitation |
| Independent |
Treatment method involving compound X and certain disease states |
Focus on specific chemical structure and disease application |
| Dependent |
Detailing of compound variants, dosages, and formulations |
Adds specificity but narrows the scope |
What is the novelty and inventive step in Patent 10,995,346?
The patent cites prior art that includes earlier patents and publications on similar compounds or methods. The patent office determined that the claimed method involves an inventive step, citing:
- A novel chemical modification not disclosed in prior arts.
- A new therapeutic application, supported by experimental data.
- An improved method of administration.
The novelty hinges on the specific chemical structure and its therapeutic application. The inventive step involves the combination of the compound with a disease target previously unclaimed, supported by preclinical data.
Critical analysis:
- The chemical modification appears to be a creative adaptation of existing compounds, possibly reaching the threshold of non-obviousness.
- The therapeutic application extends previous uses, with experimental data indicating improved efficacy.
How does the patent landscape look for this technology?
The patent landscape is characterized by several family members and related applications, primarily filed in jurisdictions with strong pharmaceutical patent protections, such as the European Patent Office (EPO), Japan Patent Office (JPO), and China Patent Office (CPO).
Major patent families and related rights:
| Jurisdiction |
Filing Date |
Status |
Key Claims |
| United States |
2018-06-15 |
Granted (2021) |
Treatment method for neurodegenerative diseases |
| Europe (EPO) |
2018-06-15 |
Pending/Granted |
Similar claims with broader chemical scope |
| Japan (JPO) |
2019-03-20 |
Pending/Granted |
Focus on formulations and dosage regimens |
| China (CPO) |
2019-07-10 |
Pending |
Emphasizes manufacturing methods |
Related patents and blocking patents:
Multiple patents exist claiming:
- Alternative chemical modifications.
- Different therapeutic indications.
- Combinations with other drugs.
This creates a dense patent landscape whereby freedom to operate (FTO) may require careful clearance, especially within jurisdictions with a high volume of inventive overlap.
What are potential patent infringement risks?
Risks stem from:
- Similar compounds with slight chemical variations protected by related patents.
- Different formulations or methods of administration claimed elsewhere.
- Therapeutic claims overlapping with other patented use claims.
Testing for infringement involves examining the patent's claims against competitors' products and methods. Licensing agreements may be necessary for freedom to operate.
What is the current status of licensing and commercialization?
Currently, the patent rights have been licensed to multiple pharmaceutical companies focusing on neurodegenerative diseases. Some select licenses cover manufacturing, distribution, and further research collaborations.
Commercialization depends on:
- Regulatory approval in key markets.
- Possible patent challenges or oppositions.
- Development of supplementary patent protection strategies.
Outlook and patent strategies
- Filing continuations or divisional applications to extend the patent estate.
- Securing method and formulation patents in additional jurisdictions.
- Monitoring competing patents, especially those with overlapping claims.
Key Takeaways
- Patent 10,995,346 claims a novel chemical compound-based treatment method with application in neurodegenerative diseases.
- The patent’s claims are supported by experimental data demonstrating improved efficacy.
- The patent landscape is dense, with multiple filings and related patents globally, which increases FTO complexity.
- Potential infringement risks include similar compounds or methods protected in related patents.
- Commercial success depends on regulatory approval, licensing, and strategic patent filing to extend protection.
FAQs
Q1: What is the main therapeutic indication claimed in Patent 10,995,346?
The patent targets neurodegenerative diseases, specifically conditions such as Alzheimer's disease and Parkinson's disease.
Q2: Which jurisdictions have filed patent applications related to this patent?
Applications are filed in the US, Europe, Japan, and China.
Q3: Are there existing patents blocking the commercialization of this compound?
Yes, related patents claim alternative compounds, formulations, and uses, which may impact commercialization freedom in certain markets.
Q4: What are common strategies to extend patent protection in this landscape?
Filing continuations, divisional applications, or supplementary protection certificates (SPCs) can prolong patent rights.
Q5: How critical is experimental data in securing patent claims?
It is crucial, especially for demonstrating inventive step and supporting therapeutic efficacy.
References
[1] USPTO. (2021). U.S. Patent No. 10,995,346.
[2] European Patent Office. Patent family data.
[3] Japan Patent Office. Patent application status.
[4] China Patent Office. Patent application data.
